Niosomal gel of lornoxicam for topical delivery: In vitro assessment and pharmacodynamic activity

AAPS PharmSciTech

Volumn 14, Issue 3, 2013, Pages 1072-1082

  Kumbhar, Deepak ^a   Wavikar, Preeti ^a   Vavia, Pradeep ^a,b  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b University under Section 3 of UGC Act 1956   (India)

Author keywords

anti inflammatory activity; lornoxicam; niosomes; rheology; texture analysis

Indexed keywords

CARBOMER; CARBOPOL 980 NF; CARRAGEENAN; CHOLESTEROL; DICETYL PALMITATE; LORNOXICAM; NIOSOME; POLYSORBATE 20; POLYSORBATE 80; SORBITAN LAURATE; SORBITAN OLEATE; SORBITAN STEARATE; STABILIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; FILM; FLOW KINETICS; GEL; HYDRATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PAW EDEMA; PRIORITY JOURNAL; RABBIT; SCANNING ELECTRON MICROSCOPY; SKIN IRRITATION; SKIN PERMEABILITY; X RAY DIFFRACTION;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALORIMETRY, DIFFERENTIAL SCANNING; GELS; LIPOSOMES; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; PIROXICAM; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84890213670     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9986-5     Document Type: Article

References (33)

1. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol. 2005;59(1):14-7.
2. Norholt SE, Sindet-Pedersen S, Larsen U, Bang U, Ingerslev J, Nielsen O, et al. Pain control after dental surgery: a double-blind, randomised trial of lornoxicam versus morphine. Pain. 1996;67(2):335-43.
3. Staunstrup H, Ovesen J, Larsen UT, Elbaek K, Larsen U, Kroner K. Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain. J Clin Pharmacol. 1999;39(8):834-41.
4. Hamza YES, Aburahma MH. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations. Drug Dev Ind Pharm. 2010;36(3):337-49.
5. Radhofer-Welte S, Dittrich P. Determination of the novel non-steroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluid. J Chromatogr B Biomed Sci Appl. 1998;707(1):151-9.
6. Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam: a short half-life oxicam. Clin Pharmacokinet. 1998;34(6):421-8.
7. Lin SZ, Wouessidjewe D, Poelman MC, Duchene D. In vivo evaluation of indomethacin/cyclodextrin complexes gastrointestinal tolerance and dermal anti-inflammatory activity. Int J Pharm. 1994;106(1):63-7.
8. Vora B, Khopade AJ, Jain N. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release. 1998;54(2):149-65.
9. Manconi M, Sinico C, Valenti D, Lai F, Fadda AM. Niosomes as carriers for tretinoin: III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int J Pharm. 2006;311(1):11-9.
10. Baillie A, Florence A, Hume L, Muirhead G, Rogerson A. The preparation and properties of niosomes - nona-ionic surfactant vesicles. J Pharm Pharmacol. 1985;37(12):863-8.
11. Azmin MN, Florence AT, Handjani-Vila RM, Stuart JFB, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol. 1985;37(4):237-42.
12. Handjani-Vila RM, Ribier A, Rondot B, Vanlerberghie G. Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmet Sci. 1979;1(5):303-14.
13. Toshimitsu Y, Florence AT. Vesicle (niosome)-in-water-in-oil (v/w/o) emulsions: an in vitro study. Int J Pharm. 1994;108(2):117-23.
14. Junginger HE, Hofland HEJ, Bouwstra JA. Liposomes and niosomes: interactions with human skin. Cosmet toiletries. 1991;106(8):45-50.
15. Reddy DN, Udupa N. Formulation and evaluation of oral and transdermal preparations of flurbiprofen and piroxicam incorporated with different carriers. Drug Dev Ind Pharm. 1993;19(7):843-52.
16. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release. 1994;30(1):1-15.
17. Van Hal D, Van Rensen A, De Vringer T, Junginger H, Bouwstra J. Diffusion of estradiol from non-ionic surfactant vesicles through human stratum corneum in vitro. STP Pharma Sci. 1996;6(1):72-8.
18. Bhalekar MR, Pokharkar V, Madgulkar A, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech. 2009;10(1):289-96.
19. Chawla V, Saraf SA. Rheological studies on solid lipid nanoparticle based carbopol gels of aceclofenac. Colloids Surf B Biointerfaces. 2012;92:293-8.
20. Park EK, Song KW. Rheological evaluation of petroleum jelly as a base material in ointment and cream formulations: steady shear flow behavior. Arch Pharm Res. 2010;33(1):141-50.
21. Chow KT, Chan LW, Heng PWS. Formulation of hydrophilic non-aqueous gel: drug stability in different solvents and rheological behavior of gel matrices. Pharm Res. 2008;25(1):207-17.
22. Jones DS, Lawlor MS, Woolfson AD. Examination of the flow rheological and textural properties of polymer gels composed of poly (methylvinylether-co- maleic anhydride) and poly (vinylpyrrolidone): rheological and mathematical interpretation of textural parameters. J Pharm Sci. 2002;91(9):2090-101.
23. Wavikar P, Vavia P. Nanolipidgel for enhanced skin deposition and improved antifungal activity. AAPS PharmSciTech. 2013;14(1):222-33.
24. Jenning V, Gysler A, Schafer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2000;49(3):211-8.
25. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131-55.
26. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm. 2003;56(2):189-96.
27. Ozguney IS, Karasulu HY, Kantarci G, Sumru S, Guneri T, Ertan G. Transdermal delivery of diclofenac sodium through rat skin from various formulations. AAPS PharmSciTech. 2006;7(4):39-45.
28. Hamza YES, Aburahma MH. Design and in vitro evaluation of novel sustained-release double-layer tablets of lornoxicam: utility of cyclodextrin and xanthan gum combination. AAPS PharmSciTech. 2009;10(4):1357-67.
29. Kandasamy R, Veintramuthu S. Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech. 2010;11(3):1119-27.
30. Abdelbary G, El-gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech. 2008;9(3):740-7.
31. Balakrishnan P, Shanmugam S, Lee WS, Lee WM, Kim JO, Oh DH, et al. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm. 2009;377(1):1-8.
32. Mali N, Darandale S, Vavia P. Niosomes as a vesicular carrier for topical administration of minoxidil: formulation and in vitro assessment. Drug Deliv Transl Res. 2012:1-6.
33. Fang JY, Hong CT, Chiu WT, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm. 2001;219(1):61-72.